PHG

Business Context and Reporting Period

Company: Koninklijke Philips N.V. (Royal Philips)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Philips is a global health technology company operating in three primary segments: Diagnosis & Treatment, Connected Care, and Personal Health. The company focuses on patient-centric innovation, AI integration, and operational simplification. In 2025, Philips completed its three-year strategic plan, emphasizing patient safety, supply chain resilience, and margin expansion.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: Net income swung from a loss of EUR 698 million in 2024 to a profit of EUR 897 million in 2025. This was driven by higher income from operations, lower tax charges, and significantly reduced Respironics-related expenses.
• Segment Performance:
  • Diagnosis & Treatment: Sales flat on a comparable basis; Adjusted EBITA margin improved to 11.7%.
  • Connected Care: Comparable sales grew 3%; Adjusted EBITA margin improved to 10.7% (up from 9.6%), aided by lower litigation provisions compared to 2024.
  • Personal Health: Strongest performer with 8% comparable sales growth and an Adjusted EBITA margin of 18.0%.
• Cost Management: Cost of sales decreased by 2% of sales. Gross margin expanded to 45% (from 43% in 2024) despite tariff impacts and cost inflation, driven by productivity actions and lower restructuring charges.
• Respironics Impact: Respironics-related charges dropped to EUR 209 million in 2025 from EUR 691 million in 2024. The company paid approximately EUR 1.1 billion in settlements related to personal injury and medical monitoring claims in the first half of 2025.

Guidance, Outlook, and Risks

2026 Outlook

• Comparable Sales Growth: 3% - 4.5%
• Adjusted EBITA Margin: 12.5% - 13.0%
• Free Cash Flow: EUR 1.3 - 1.5 billion

Mid-Term Targets (2026-2028)

• Mid-single-digit CAGR for comparable sales growth.
• Adjusted EBITA margin in the mid-teens by 2028.
• Cumulative Free Cash Flow of EUR 4.5 - 5.0 billion.
• EUR 1.5 billion in productivity savings.

Management Commentary

CEO Roy Jakobs highlighted the completion of the three-year plan, noting strengthened fundamentals, improved order intake (6% comparable growth), and a culture shift toward "impact with care." The company launched a new 2026-2028 plan focused on profitable growth and sustainable value.

Risks and Contingencies

• Regulatory & Quality: In September 2025, the FDA issued a warning letter following inspections at three facilities. Philips remains under a consent decree with the US DOJ and FDA regarding Respironics.
• Geopolitical & Tariffs: Ongoing geopolitical tensions and tariff developments continue to impact supply chains and costs. The company has taken steps to regionalize supply chains to mitigate these risks.
• Legal Proceedings: While major US settlements were finalized, investigations by the DOJ and state Attorneys General continue. Securities class actions remain pending in the US and Netherlands.

Investor Verification Checklist

• Respironics Remediation Status: Verify the progress of the remaining field action (approx. 65,000 devices) and the status of ongoing DOJ investigations and state-level inquiries.
• FDA Warning Letter Resolution: Monitor the company's response to the September 2025 FDA warning letter and subsequent inspection outcomes.
• Tariff Impact on Margins: Assess the sustainability of margin expansion given the 3% tariff cost impact on cost of sales and potential for further trade restrictions.
• Free Cash Flow Volatility: Note that 2025 Free Cash Flow was impacted by a EUR 1.025 billion cash payment for Respironics settlements; verify if 2026 guidance accounts for similar one-off outflows.
• Acquisition Integration: Review the integration progress of SpectraWAVE, Inc. (acquired Jan 2026) and its contribution to the Diagnosis & Treatment segment.